Home

According to the company, the FA-1 is the world’s first wearable device for presurgical vein dilation that promotes arteriovenous fistula (AVF) creation in adult patients diagnosed with chronic renal failure whose preoperative assessment of the venous anatomy suggests that superficial arm vein or perforator vein size is inadequate for the creation of an AVF for haemodialysis access.

Access to the FA-1 device by patients with an end-stage renal disease (ESRD) vein dilation indication is now expedited through the FDA Breakthrough Device programme—which is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions, such as ESRD.

The programme provides Fist Assist with priority FDA review and interactive communication regarding device development, clinical data, and future indication applications, during the premarket review process, according to a press release from the company.

“As this is a first-of-its-kind wearable device for haemodialysis patients focused on presurgery vein dilation, we are ecstatic to have the FDA recognise this innovative approach to vein dilation and the potential of this therapeutic wearable device that supports the patient’s journey through ESRD,” said Hrishikesh Gadagkar, Fist Assist regulatory advisor and CEO of Idonea Solutions. “We appreciate the FDA’s thorough review of Fist Assist’s Breakthrough Device designation request and look forward to a collaborative relationship as the company develops its FDA de novo classification application.”

The FA-1 device is a wearable, intermittent pneumatic compression device that is worn on the arm to promote vein dilation. The device compresses the outflow vein, which has both biological and physiological benefits, and—because it is automated—the FA-1 device significantly improves patients’ compliance compared to other vein dilation alternatives.

“This designation is another major milestone for Fist Assist Devices. We expect it to change the algorithm for patient care,” said Tej Singh, founder and CEO of Fist Assist. “The recently published data from the FACT trial on stage 4 vein dilation and pFACT trial on perforator vein dilation confirms the value of intermittent vein compression to CKD [chronic kidney disease] patients.

“The FA-1 device benefits patients, physicians and healthcare delivery systems because larger veins give patients more treatment options regarding surgical or endoAVF procedures. Ultimately, our goals are to help patients achieve better outcomes and have more hope. This designation gets us one step closer to accomplishing our goals.”

Source VascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Fist Assist receives FDA Breakthrough Device designation for wearable vein dilation device

Chia sẽ qua google bài: Fist Assist receives FDA Breakthrough Device designation for wearable vein dilation device

Chia sẽ qua twitter bài: Fist Assist receives FDA Breakthrough Device designation for wearable vein dilation device

Chia sẽ qua MySpace bài: Fist Assist receives FDA Breakthrough Device designation for wearable vein dilation device

Chia sẽ qua LinkedIn bài: Fist Assist receives FDA Breakthrough Device designation for wearable vein dilation device

Chia sẽ qua stumbleupon bài: Fist Assist receives FDA Breakthrough Device designation for wearable vein dilation device

Chia sẽ qua icio bài: Fist Assist receives FDA Breakthrough Device designation for wearable vein dilation device

Chia sẽ qua digg bài: Fist Assist receives FDA Breakthrough Device designation for wearable vein dilation device

Chia sẽ qua yahoo bài: Fist Assist receives FDA Breakthrough Device designation for wearable vein dilation device

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.